Previous investigations conclude that high age, preceding diarrhea, and high GBS disability score are predictors for poor recovery. 9 These factors also constitute the modified Erasmus GBS outcome score (mEGOS) which has been validated for prediction of GBS outcome at 4 weeks, 3 and 6 months. 10 Alternative scoring systems are developed and need to be evaluated in the future studies. 11 High cerebrospinal fluid (CSF) levels of neurofilament heavy protein (NFH), a biomarker for axonal damage, obtained in close relation to GBS onset were related to severe disability at follow-up [12] [13] [14] The aim of this study was to investigate whether clinical features, neurophysiological examination, and neurospecific biomarkers in CSF, obtained at the acute stage of GBS, could predict patients at risk for poor outcome at long-term follow-up 9-17 years after GBS onset.
| MATERIAL AND ME THODS

| Study population
Fifty-one patients with a suspected diagnosis of GBS were consecutively admitted to the Department of Neurology at Sahlgrenska University Hospital, Gothenburg, Sweden, from November 1989 to January 1997. The diagnostic work-up included registration of a preceding infection or vaccination, acute and convalescent serology for infections (mycoplasma, cytomegalovirus, adenovirus, RS-virus, and influenza type A, Campylobacter jejuni), nerve conduction studies (NCS) and electromyography (EMG), and routine CSF analysis (cell count, protein level, albumin ratio, 15 oligoclonal IgG bands 16 ).
Medical records for these patients were reassessed 9-17 years after hospitalization in the year 2006, and a follow-up study was performed.
Only patients with a monophasic disease that fulfilled the diagnostic criteria of GBS 6 were included in the study. At follow-up, 11 patients had died (by other causes than GBS) and 11 patients were excluded, 6
of these had other diagnosis (1 HIV-associated neuropathy, 1 toxic neuropathy, 1 arachnoiditis, 3 undefined neuropathy) and 5 had variants of GBS not fulfilling the classical criteria (1 Miller Fischer syndrome, 4 relapsing chronic inflammatory demyelinating polyneuropathy). Three patients were lost to follow-up, and 8 declined participation in the study ( Figure 1) . Thus, 18 patients, 8 males and 10 females, participated in this study. Demographic, clinical, and laboratory characteristics of patients and healthy controls are presented in Table 1 . The regional ethical board of Gothenburg University approved the study. All patients and controls gave their informed consent to inclusion in the study.
Neurofilament light protein analyses were performed at the reassessment of patients 2006 and once again 2017 ( Figure 2 ). Since the analyses were made at different occasions, using different immune assays, CSF from 36 healthy subjects served as controls for analyzing GFAP and NFL with polyclonal assays, 17, 18 and 28 healthy subjects served as controls, when analyzing NFL with the monoclonal assay. 
| Clinical and neurophysiological assessment
Clinical examination of patients was performed shortly after disease onset (median 19 days, range 4-28 days) by either of two experienced neurologists. Results from these examinations and data from the medical records were used to assign a functional score at GBS nadir for each patient, in accordance to the Hughes functional score 20 ranging from F-score 0 (no symptoms) over increasing functional deficit/walking restriction to a maximum of 6 (dead). The second assessment was made by a third neurologist at follow-up 9-17 years after GBS (median 13 years) with registration of overall disability sum score (ODSS) 21 and F-score. An F-score of ≥3 (not being able to walk independently) at follow-up was classified as "poor outcome" and an F-score < 3 as "good outcome". 13 In addition, we retrospectively assessed patients with the mEGOS at hospital admission and again in 12 patients at day 7 of admission. 10 The mEGOS is a composite score for prediction of GBS outcome and depends on age, preceding diarrhea, and assessment of muscle strength, using the Medical Research Council (MRC) sum score. 10, 22 The neurophysiological examination was performed shortly after GBS onset, median 15 (4-34) days, and included NCS and EMG using standard protocols. The examinations were performed at the 
| Sampling of peripheral blood and CSF
Samples of peripheral blood and CSF were obtained in close relation to the initial neurological examination. Except for not using atraumatic needles, the lumbar puncture and handling of samples used similar procedures that are now recommended in the consensus protocol of the BioMS-EU network for CSF collection and biobanking. 25 The first 12 mL of CSF was carefully mixed, and after centrifugation, fractions were frozen and stored in 0.5 mL aliquots at −80°C. 
| Neurofilament light protein assay
Neurofilament light protein was determined in CSF 9-17 years after the sampling at the disease onset in the year 2006 with enzyme-linked immunosorbent assay (ELISA) using polyclonal antibodies against NFL 17 (unpublished data) and in this study once again, using the Uman Diagnostics NF-light ELISA as previously described. 19 The latter test has improved analytical sensitivity that allows for quantification of NFL concentration in CSF from healthy controls, that is, considerably lower concentrations.
In brief, the assay is based on two highly specific monoclonal antibodies and a biotin-streptavidin horseradish peroxidase (HRP) system. Analysis was performed at room temperature. CSF samples were diluted 1:1 with sample dilution buffer to a total volume of 100 μL and incubated with agitation (800 rpm) for one hour in precoated anti-NFL ELISA plates.
Thereafter, a 100 μL solution of tracer antibody (biotin anti-NFL) was added to each well and incubated for 45 minutes. Washing cycles were performed after all incubations. Detection was performed using 100 μL streptavidin-HRP incubated for 30 minutes, followed by another incubation with 100 μL 3,30,5,50-tetramethylbenzidine for 15 minutes. A volume of 50 μL stop solution (8% v/v sulfuric acid) was added to each well, and absorbance was read at λ 490 nm. The analytical sensitivity of the NFL assay was 31 ng/L.
| Glial fibrillary acidic protein assay
Glial fibrillary acidic protein (GFAP) was measured with a previously described ELISA procedure. 18 In brief, capturing antibody (hen anti-GFAP IgG) was absorbed to microplates. CSF samples or reference GFAP was added and incubated for 2 hours at room temperature.
Rabbit anti-GFAP IgG was then added and incubated for 1 hour at room temperature. Captured secondary antibody was detected using peroxidase-conjugated donkey anti-rabbit IgG. The analytical sensitivity of the GFAP assay was 16 ng/L.
| Statistics
The Mann-Whitney U test was used to compare groups.
Spearman's rank correlation coefficient was used to discern 
| RE SULTS
| Clinical measures for long-term outcome
Clinical, neurophysiological, and laboratory results, obtained during the acute phase of GBS (Table 1) , were used to characterize patients with good and poor outcome at follow-up (Table 2) . At the acute phase of GBS, 12 patients had severe disability (FS 4-6; bedridden, need of assisted ventilation), six had moderate (FS 2-3; able to walk 10 meters with or without support), and none had mild or no disability (FS 0-1). In three patients, all in the severely afflicted group, mechanical ventilation was needed. Eleven of the severely disabled patients (92%), and three patients (50%) with moderate disability, were treated with 4-5 plasma exchanges or 5 days of i.v. high dose of immunoglobulin infusions (IVIG). At follow-up 9-17 years after the GBS onset, one patient had severe residual disability (FS 4), four had moderate (FS 2-3) disability, and 14 had mild (FS 0-1) disability; 7 of these were in complete remission (FS-score 0, no pathological findings in neurological examination or ODSS-scoring, Table 2 ). The long-term outcome was considered good (FS < 3, capable of independent walking) in 15 of 18, (83%) and poor (FS 3-6, in need of assisted walking), in 3 of 18 patients (17%). Higher age, preceding diarrhea, and Campylobacter jejuni infection were associated with poor outcome. Age was independently predicting for a worse outcome (ODSS r = .52, P < .05, F-score r = .59, P < .01). The disability (MRC sum score) at admission did not predict a worse outcome but did 7 days after admission (FS r =−.61, P < .05, ODSS r = .71, P < .01). In addition, the TA B L E 1 Demographic, clinical, and laboratory characteristics of patients at GBS nadir and healthy controls mEGOS predicted outcome. Patients with poor long-term outcome had a significantly higher mEGOS at GBS onset (P < .01) and day 7 (P < .05) compared with that obtained in patients with good outcome. The median mEGOS for the whole group was 4 (0-9) at admission and 5 (0-12) at day 7 and both correlated with the longterm ODSS outcome (r = .654, P < .01 and r = .709, P < .01) and the FS (r = .59, P = .01 and r = .579, P < .05).
| Neurophysiological assessments
The neurophysiological examination, performed 15 days (median, range 4-39 days) from symptom onset, included NCS and EMG (n = 14) or only NCS (n = 4). The NCS and EMG examination was compatible with primary demyelinating neuropathy in 11 patients (5 pure motor, 1 pure sensory, and 5 sensory-motor), 1 primary axonal, and 3 were considered normal. 5 Four patients were either not examined or could not be classified. No association was found between the results of the neurophysiological investigation and the severity or outcome of GBS or to the levels of NFL or GFAP.
| NFL and GFAP concentrations for predicting long-term outcome
Patients had significantly higher NFL and GFAP levels in CSF compared with healthy controls (P < .0001 and P < .05, respectably, Table 1 ), and these differences were still statistically significant after controlling for age, preceding diarrhea, and GBS disability score at nadir. Patients with poor outcome (F-score 3 or worse; incapable of independent walking) had significantly higher NFL levels than those with good outcome (P < .01, Table 2 ). Patients with NFL levels above 10.000 ng/L (n = 6, arbitrary determined as five times the highest level of healthy controls) had persistent disability at follow-up with a median ODSS of 5.5 (range 2-10) as compared to 0 (range 0-3) in patients with NFL concentrations below this limit (P < .001, Table 2 ).
NFL and GFAP concentrations did not differ between patients in need of assisted ventilation at nadir and those with less respiratory impairment. The NFL levels determined with a previous polyclonal assay 17 correlated with the results obtained with the monoclonal assay, 19 (r = .989, P < .001, Figure S1 ).
| The influence on QoL from GBS
The initial severity of GBS influenced QoL at follow-up ( Figure 3 ). The 
| Correlations between NFL, GFAP, clinical outcomes, and QoL
The NFL level correlated with disability (F-score) in the acute phase of GBS (r = .59, P = .01) and was strongly predictive of persistent disability, as measured by the F-score (r = .69, P < .001) and the ODSS score (r = .52, P < .05) at follow-up. NFL levels were dependent on age in the control group (r = .70, P < .0001), independent of gender, and correlated with the albumin ratio (function of the blood-brain barrier) in patients (r = .65, P < .005). Although patients were of older age than controls, the correlation between impairment and NFL at follow-up remained statistically significant also after correction for age; F-Score (r = .81, P < .0001) and ODSS (r = .83, P < .0001) and for both age and albumin ratio; F-score (r = .71, P < .01) and ODSS Despite an interval of 11 years between the first analysis of NFL, using the polyclonal ELISA, and the second analysis, using the monoclonal ELISA, the correlation between the results from the immunoassays was almost perfect (r = .99, P < .001) Figure S1 .
| D ISCUSS I ON
We showed that high NFL levels in CSF, obtained during the acute phase of GBS, were predictive of poor clinical outcome and worse QoL. Our results confirm the results of a previous investigation, demonstrating the predictive value of the heavy subunit of the neurofilament protein in GBS 12 . It showed that patients with high NFH levels had worse functional and motor outcome at a median followup time of 175 days after GBS onset. GFAP has been investigated previously in the acute phase of GBS and at 6 months of follow-up as a prognostic CSF biomarker. 26 However, these results have been questioned of methodological reasons 27 and we could not confirm them in our end-stage follow-up. We found no correlation between CSF GFAP levels and disruption of the blood-brain barrier (albumin quotient) in this study. Although, GFAP is expressed by Schwann cells after experimental nerve injury leading to denervation and Wallerian degeneration. 28, 29 The increased GFAP levels found in CSF of GBS patients probably reflect glial reactivity occurring in inflamed nerve roots.
Although recovery in GBS occurs primarily during the first 6 months, it may continue even beyond 12 months and significant improvement has been recorded between 6 months (57%) and 12 or 24 months of follow-up (70% and 82%, respectively). 30 We based our results on both clinical and QoL assessments, carried out 9-17 years after GBS onset when no further improvement was expected. In a previous investigation of GBS, patients with axonal involvement were more disabled and had poorer recovery than patients with demyelinating forms of the disease. 6 Both NFL and NFH are structural elements of axons, and increased levels of neurofilaments in CSF have also been observed in patients with traumatic, ischemic, degenerative, and inflammatory injuries of the central nervous system.
31
In contrast, GBS is considered an immune-mediated demyelinating disorder of the peripheral nervous system. The release of NFL to the CSF compartment is probably due to axonal damage of nerve roots and may be influenced by the disruption of the blood-nerve barrier (BNB) and the blood-CSF barrier (BCB). However, extensive deterioration of BNB/BCB may also allow NFL released to peripheral blood from damaged peripheral nerves, to enter the CSF.
In the present study, the clinical assessment was performed with the Hughes functional score 20 and the ODSS. 21 A recent study showed high predictive value of mEGOS if scoring was conducted early in GBS. 10 In the present study, retrospective scoring with the mEGOS confirmed its predictive value. Patients with poor outcome had higher age, two of three patients had preceding diarrhea, and the MRC at day 7 after admission had predictive value. In this study, these data were extracted from medical records retrospectively.
Another shortcoming of the present study was the incomplete and inadequately standardized neurophysiological investigation of patients. We used the Hadden electrodiagnostic criteria for GBS. 5 Recently, modified electrodiagnostic criteria showed that the characterization of patients may be improved. 32 However, the available data did not allow a transformation into these criteria retrospectively.
Although the number of included patients in this study was lim- Interestingly, the two NFL immune assays showed similar results and the correlation between the methods was extremely high. Thus, storing CSF samples at −80°C for 20-28 years seemed not to affect the NFL level, indicating NFL as extremely stable during such conditions.
In conclusion, high CSF NFL concentrations at GBS onset were predictive of long-term disability and worse QoL. The results support that axonal damage is the major explanation of sustained disability in GBS. CSF NFL could improve the detection of patients with poor long-term outcome. Our findings suggest that NFL should be included as an early indicator of patients in need of extensive medical and rehabilitating efforts on a long-term basis. Moreover, patients with severe disability at GBS onset but with low NFL concentrations in CSF seem to have a much better chance of recovery than those with increased CSF NFL concentrations. 
ACK N OWLED G EM ENTS
CO N FLI C T O F I NTE R E S T S
MA has received compensation for lectures and/or advisory boards 
